HOME › DRUGS › CHARACTERISED VIABLE AUTOLOGOUS CARTILAGE CELLS EXPANDED EX VIVO EXPRESSING SPECIFIC MARKER PROTEINS
ACTIVE SUBSTANCE / INN

CHARACTERISED VIABLE AUTOLOGOUS CARTILAGE CELLS EXPANDED EX VIVO EXPRESSING SPECIFIC MARKER PROTEINS

Brand name(s): ChondroCelect
EMA LISTED
WITHDRAWN
Cartilage Diseases
ACTIVE SUBSTANCE
Characterised Viable Autologous Cartilage Cells Expanded Ex Vivo Expressing Specific Marker Proteins
REGULATORS
EMA
SPONSORS / MAH
TiGenix N.V.
TOTAL APPLICATIONS
1
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
ChondroCelectTiGenix N.V.Withdrawn05/10/2009Cartilage Diseases

FULL INTELLIGENCE ON CHARACTERISED VIABLE AUTOLOGOUS CARTILAGE CELLS EXPANDED EX VIVO EXPRESSING SPECIFIC MARKER PROTEINS

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →